Cochrane · systematic review · CD011645
Pharmacological interventions for acute hepatitis B infection
Mantzoukis, K, Rodríguez‐Perálvarez, M, Buzzetti, E, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Hepato-BiliaryAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
8
No studies
6
Included studies
NR
No studies 6 · 42.9%Ungraded 0 · 0%Very low 7 · 50%Low 1 · 7.1%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Lamivudine versus no intervention for acute hepatitis B virus infection
Population: people with acute HBV infection
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Short‐term mortality (< 1 year) Lamivudine vs no intervention | OR 1.29 [0.33, 4.99] | 2 studies · 250 participants | Very low Downgraded: risk of bias, imprecision |
Progression to chronic HBV infection (6 to 12 months) Lamivudine vs no intervention | OR 1.99 [1.05, 3.77] | 3 studies · 285 participants | Very low Downgraded: risk of bias, imprecision |
Progression to fulminant HBV infection Lamivudine vs no intervention | no estimate extracted | NR | No studies |
Serious adverse events (6 to 12 months) Lamivudine vs no intervention | no estimate extracted | 2 studies · 250 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events (proportion) (12 months) Lamivudine vs no intervention | OR 1.42 [0.34, 5.94] | 1 study · 35 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events (number of events) (12 months) Lamivudine vs no intervention | Rate ratio 1.72 [1.01, 2.91] | 1 study · 35 participants | Very low Downgraded: risk of bias, imprecision |
Health‐related quality of life (1 week) Lamivudine vs no intervention | no estimate extracted | NR | No studies |
Interferon versus no intervention for acute hepatitis B virus infection
Population: people with acute HBV infection
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Short‐term mortality Interferon vs no intervention | no estimate extracted | NR | No studies |
Progression to chronic HBV infection Interferon vs no intervention | no estimate extracted | NR | No studies |
Progression to fulminant HBV infection Interferon vs no intervention | no estimate extracted | NR | No studies |
Serious adverse events Interferon vs no intervention | no estimate extracted | 1 study · 100 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events (proportion) (4 to 6 months) Interferon vs no intervention | OR 348.16 [45.39, 2670.26] | 2 studies · 200 participants | Low Downgraded: risk of bias, imprecision |
Adverse events (number of events) Interferon vs no intervention | no estimate extracted | NR | No studies |
Health‐related quality of life (1 week) Interferon vs no intervention | no estimate extracted | 1 study · 100 participants | Very low Downgraded: risk of bias, imprecision |